CAY10603

1045792-66-2

C22H30N4O6

DMSO : >= 50 mg/mL (111.98 mM)

Epigenetics; Cell Cycle/DNA Damage

CAY10603 (BML-281) is a potent and selective HDAC6 inhibitor, with an IC₅₀ of 2 pM; CAY10603 (BML-281) also inhibits HDAC1, HDAC2, HDAC3, HDAC8, HDAC10, with IC₅₀s of 271, 252, 0.42, 6851, 90.7 nM. IC50 & Target: IC50: 2 pM (HDAC6), 0.42 nM (HDAC3), 90.7 nM (HDAC10), 252 nM (HDAC2), 271 nM (HDAC1), 6851 nM (HDAC8)^[1] In Vitro: CAY10603 (Compound 7) shows potent inhibitory activities against pancreatic cancer cell lines, with IC₅₀s of 1, 0.3, 0.1, 0.1, 0.6, <1, 0.5 uM for BxPC-3, HupT3, Mia Paca-2, Panc 04.03, SU.86.86, HMEC, HPDE6c7, respectively. CAY10603 (100 nM, 200-300 nM) is active against both the Mia Paca-2 and Panc04.03 cell lines^[1]. CAY10603 inhibits HDAC6 deacetylase activity, and supresses the proliferation of lung adenocarcinoma cells. CAY10603 also induces apoptosis of lung adenocarcinoma cells. Furthermore, CAY10603 synergizes with gefitinib to induce apoptosis in lung adenocarcinoma cell lines, partly through the destabilization of EGFR and inactivation of the EGFR pathway^[2].